Clinical Practice of AECOPD Management in China
A Non Interventional, Retrospective Study on AECOPD Treatment Status in China
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Beijing, China
- Research Site
-
Guang Zhou, China
- Research Site
-
Shanghai, China
- Research Site
-
Tianjin, China
- Research Site
-
-
Anhui
-
Hefei, Anhui, China
- Research Site
-
-
Beijing
-
Beijing, Beijing, China
- Research Site
-
-
Hebei
-
Langfang, Hebei, China
- Research Site
-
-
Inner Mongolia
-
Baotou, Inner Mongolia, China
- Research Site
-
Hohhot, Inner Mongolia, China
- Research Site
-
-
Ningxia
-
Yinchuan, Ningxia, China
- Research Site
-
-
Shanghai
-
Shanghai, Shanghai, China
- Research Site
-
-
Shanxi
-
Taiyuan, Shanxi, China
- Research Site
-
Xi'an, Shanxi, China
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- ≥40 years old
- Hospitalization treatment due to AECOPD since Sep, 2013
- Diagnosed by GOLD 2013 as COPD at least 3 months before AECOPD based on treating physician's judgment
- Provided informed consent or informed consent waiver
Exclusion Criteria:
- Participation in any interventional clinical study within 3 months before being recruited in the study.
- Ongoing AECOPD during recruitment timeline
- The patients whose symptoms haven't recovered and then discharge by themselves
- The primary diagnosis of hospitalization is not AECOPD
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of glucocorticoids treatment for AECOPD
Time Frame: day 1 to up to 30 days (Hospital discharge)
|
day 1 to up to 30 days (Hospital discharge)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of oral /intravenous/ inhaled steroid therapy in patients treated with glucocorticoids, mean dosage, regimen and treatment duration via different administration route in hospital
Time Frame: day 1 to up to 30 days (Hospital discharge)
|
day 1 to up to 30 days (Hospital discharge)
|
|
Percentage of antibiotics treatment for AECOPD by clinicians during the hospitalization.
Time Frame: day 1 to up to 30 days (Hospital discharge)
|
day 1 to up to 30 days (Hospital discharge)
|
|
Mortality caused by AECOPD and recorded as primary cause of death by clinicians
Time Frame: day 1 to up to 30 days (Hospital discharge)
|
day 1 to up to 30 days (Hospital discharge)
|
|
Percentage of antibiotics treatment via different administration route for AECOPD, mean treatment duration via different administration route in hospital
Time Frame: day 1 to up to 30 days (Hospital discharge)
|
day 1 to up to 30 days (Hospital discharge)
|
|
Endotracheal intubation rate in treatment of AECOPD
Time Frame: day 1 to up to 30 days (Hospital discharge)
|
day 1 to up to 30 days (Hospital discharge)
|
|
Pneumonia rate at the diagnose of AECOPD and in treatment of AECOPD
Time Frame: day 1 to up to 30 days (Hospital discharge)
|
day 1 to up to 30 days (Hospital discharge)
|
|
Hospitalization duration and treatment cost due to AECOPD as primary cause
Time Frame: day 1 to up to 30 days (Hospital discharge)
|
day 1 to up to 30 days (Hospital discharge)
|
|
Percentage of treatment category before AECOPD and at discharge
Time Frame: day 1 to up to 30 days (Hospital discharge)
|
day 1 to up to 30 days (Hospital discharge)
|
|
Clinical efficacy and safety within different administration route of corticosteroid treatment
Time Frame: day 1 to up to 30 days (Hospital discharge)
|
day 1 to up to 30 days (Hospital discharge)
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Demographic data
Time Frame: day 1
|
day 1
|
|
Year of COPD diagnosis
Time Frame: day 1
|
day 1
|
|
Any other significant medical condition or co-morbidities
Time Frame: day 1
|
day 1
|
|
Smoking status (number of pack-years)
Time Frame: day 1
|
day 1
|
|
Onset date of this AECOPD, date of hospitalization, date of discharge
Time Frame: day 1 to up to 30 days (Hospital discharge)
|
day 1 to up to 30 days (Hospital discharge)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Wanzhen Yao, Ph.D, Peking University Third Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NIS-RCN-XXX-2013/1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.